Introduction Immune checkpoint inhibitors (ICIs), by blocking negative regulatory signals on T cells, have revolutionized the treatment paradigm for advanced cancers by reinvigorating antitumor immunity.1,2 However, the overactivation of the immune system acts as a “double-edged sword”, potentially harming the host while attacking the tumor, leading to immune-related adverse events (irAEs).3 In the clinical practice of managing these toxicities, an intriguing observation has emerged: patient...
